Understanding The Potential of STK11 as A Drug Target Or Biomarker

Target Name: STK11

NCBI ID: G6794

STK11

Understanding The Potential of STK11 as A Drug Target Or Biomarker

STK11 (also known as LKB1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has led to a great deal of interest in the field of biotechnology.

STK11 is a small RNA molecule that is found in all cell types. It is composed of a single exon and has a length of approximately 200 nucleotides. The exon is located at position -3, and the 5' end is marked by a stem-loop structure. This stem-loop structure is the hallmark of a small RNA molecule, and is known as a microRNA (miRNA).

STK11 has been shown to play a role in various cellular processes, including cell growth, differentiation, and apoptosis. It has been shown to regulate the expression of other genes, including cancer-related genes. For example, studies have shown that STK11 can inhibit the activity of the oncogene bad homozygous (BH), which is a gene that is commonly mutated in cancer. This suggests that STK11 may have potential as a cancer therapeutic.

In addition to its role in cancer, STK11 has also been shown to be involved in a variety of other cellular processes. For example, it has been shown to play a role in cell signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and apoptosis, and is a key regulator of many cellular processes.

STK11 has also been shown to be involved in the regulation of cellular memory. This is an important process that is involved in the retention of information and the recall of memories. Studies have shown that STK11 can regulate the expression of genes that are involved in cellular memory, suggesting that it may be a potential therapeutic target for conditions such as Alzheimer's disease.

In addition to its potential as a drug target or biomarker, STK11 has also been shown to have potential as a diagnostic tool. This is because its expression can be easily detected using RNA sequencing (RNA-seq), a technique that allows researchers to identify and quantify the expression of specific genes in a sample. This makes it possible to use STK11 as a diagnostic biomarker for a variety of diseases, including cancer.

Some studies have also shown that STK11 may have potential as a therapeutic target for other conditions, including genetic disorders and neurodegenerative diseases. For example, studies have shown that STK11 can be expressed in the brains of individuals with certain genetic disorders, such as Huntington's disease and Alzheimer's disease. This suggests that it may be a potential therapeutic target for these conditions.

In conclusion, STK11 is a small RNA molecule that has been shown to play a role in various cellular processes, including cell growth, differentiation, and apoptosis. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has led to a great deal of interest in the field of biotechnology. Further research is needed to fully understand the role of STK11 in various cellular processes and its potential as a therapeutic target or diagnostic tool.

Protein Name: Serine/threonine Kinase 11

Functions: Tumor suppressor serine/threonine-protein kinase that controls the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis and DNA damage response. Acts by phosphorylating the T-loop of AMPK family proteins, thus promoting their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not MELK. Also phosphorylates non-AMPK family proteins such as STRADA, PTEN and possibly p53/TP53. Acts as a key upstream regulator of AMPK by mediating phosphorylation and activation of AMPK catalytic subunits PRKAA1 and PRKAA2 and thereby regulates processes including: inhibition of signaling pathways that promote cell growth and proliferation when energy levels are low, glucose homeostasis in liver, activation of autophagy when cells undergo nutrient deprivation, and B-cell differentiation in the germinal center in response to DNA damage. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton. Required for cortical neuron polarization by mediating phosphorylation and activation of BRSK1 and BRSK2, leading to axon initiation and specification. Involved in DNA damage response: interacts with p53/TP53 and recruited to the CDKN1A/WAF1 promoter to participate in transcription activation. Able to phosphorylate p53/TP53; the relevance of such result in vivo is however unclear and phosphorylation may be indirect and mediated by downstream STK11/LKB1 kinase NUAK1. Also acts as a mediator of p53/TP53-dependent apoptosis via interaction with p53/TP53: translocates to the mitochondrion during apoptosis and regulates p53/TP53-dependent apoptosis pathways. Regulates UV radiation-induced DNA damage response mediated by CDKN1A. In association with NUAK1, phosphorylates CDKN1A in response to UV radiation and contributes to its degradation which is necessary for optimal DNA repair (PubMed:25329316)

The "STK11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STK11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets